Supplemental Figure 4 from Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts

Authors:

AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam Kumar Selvaraju
Ram Kumar Selvaraju
HLHans Lundqvist
Hans Lundqvist
CHCamilla Hofström
Camilla Hofström
HPHelena Persson
Helena Persson
CJC. Christofer Juhlin
C. Christofer Juhlin
JZJan Zedenius
Jan Zedenius
FFFredrik Y. Frejd
Fredrik Y. Frejd
MNMarika Nestor
Marika Nestor

Open Access

Publisher website

Google Scholar

17 June 2026

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/1535-7163.32710241

Abstract

Supplemental Figure 4: Biodistribution of BHT-101 therapy mice. Left: Biodistribution of animals carrying BHT-101 xenografts treated with 177Lu-UU-40 (6.5 MBq) dissected on the day of termination due to reaching TBL. Right: Biodistribution of animals carrying BHT-101 xenografts treated with isotype control antibody, 177Lu-B1-8 (7 MBq), dissected on the day of termination due to reaching TBL.

Keywords

SUPPLEMENTAL FIGURE
THERAPEUTIC EVALUATION
ANAPLASTIC THYROID
THYROID CANCER
ANTIBODY-BASED RADIOPHARMACEUTICAL
CANCER XENOGRAFTS
THERAPY MICE
FIGURE
XENOGRAFTS SUPPLEMENTAL
REACHING TBL